Oruka Therapeutics’ Post

Have you heard of the condition Wegener’s Granulomatosis? It is now commonly known as Granulomatosis with Polyangiitis (GPA) which is a rare autoimmune disease affecting the blood vessels. In this video, we explore the latest advances in diagnosis, treatment, and research for Wegener’s Granulomatosis. We’ll dive into the new medications, biologics, and therapies that are improving patient outcomes, as well as the innovative research shedding light on the causes and potential cures for this condition. https://buff.ly/4hrLWeG Act Now to Maximize Your Returns! If you're an accredited investor and wanting to learn more, click this Calendly link to schedule a free consultation call with Dr. Harvey Tran https://buff.ly/3YKpIwV

Join our BootCamp and dive into comprehensive sessions on Rheumatology, including DMARDs, Biologics, and living with Inflammatory Arthritis. Learn beyond the basics of Rheumatoid Arthritis and equip yourself with essential knowledge. Don't miss out – register today! https://lnkd.in/esC7TjiH #Rheumatology #BootCamp #InflammatoryArthritis #GrandRapids #MedicalEducation

Join our BootCamp and dive into comprehensive sessions on Rheumatology, including DMARDs, Biologics, and living with Inflammatory Arthritis. Learn beyond the basics of Rheumatoid Arthritis and equip yourself with essential knowledge. Don't miss out – register today! https://lnkd.in/esC7TjiH #Rheumatology #BootCamp #InflammatoryArthritis #GrandRapids #MedicalEducation

U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)   We are thrilled to share that the U.S. FDA has granted Breakthrough Therapy Designation to our therapeutic candidate, tividenofusp alfa (DNL310), for the treatment of Hunter syndrome (MPS II). Read more here: https://lnkd.in/emTs7S6y   The designation reflects the urgent need for therapies that treat both brain and body, addressing the full spectrum of Hunter syndrome, a progressive and devastating disease. We look forward to submitting a Biologics License Application (BLA) in early 2025 for review under an accelerated approval pathway.   We recognize the collective efforts that have supported this progress, and we look forward to continued collaboration with the FDA to bring an effective therapy to the Hunter syndrome community as soon as possible.     #HunterSyndrome #RareDisease

📣 𝐅𝐃𝐀 𝐂𝐥𝐞𝐚𝐫𝐬 𝐅𝐢𝐫𝐬𝐭 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬13 𝐑𝐍𝐀-𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 The FDA has cleared HuidaGene Therapeutics's investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter clinical trials. HG202 is designed to treat neovascular age-related macular degeneration, which is a leading cause of blindness in people over the age of 60. Read more in our latest update: https://lnkd.in/dAyvEm6Q #crisprmedicinenews #crisprmedicine #huidagenetherapeutics #crispr #rnaediting #genediting #blindness HuidaGene Therapeutics Alvin Luk

Our President and CEO, Dr. Judy Chou, recently sat down with Xtalks to discuss her journey in the biopharmaceutical industry and the vision behind AltruBio, driven by her passions for science, innovation, and helping patients. She spoke about AltruBio’s first-in-class immune checkpoint enhancer (#ICE), designed to address diseases at their source, and our ongoing clinical trial in ulcerative colitis.   Watch the interview here: https://lnkd.in/gYCpW4de   #HealthcareInnovation #BiotechLeadership #PatientCare #UlcerativeColitis

It's Trivia Tuesday! This question is from our article Drugs for Plaque Psoriasis https://bit.ly/4e5OoWf Answer: a Topical corticosteroids are generally used first for treatment of mild-moderate plaque psoriasis. Biologics are the most effective for moderate-severe disease.

Biotech Initiates Phase III Trial for Heart Disease Drug: https://ow.ly/vMx450Ubokc Clinical-stage life sciences company Cardiol Therapeutics Inc. is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock. $CRDL #biotechstocks

🚨A reminder to register for the upcoming webinar on how to accelerate the development and production of AAV-based therapeutics!  Learn from Regeneron’s Marília Barros and Refeyn’s Matthew Ranaghan about the best analytical strategies to analyze the ratios of empty/full/partial AAV ratios, capsid titers, sample purity and other key quality attributes essential for successful drug development. And of course, how to integrate #MassPhotometry in your workflows for fast, sample-efficient analysis. 🔬📊  Register here 👉 https://lnkd.in/dfMqa7dY

PROPEL is evaluating a lower dose and a higher dose of PR001 in 2 separate cohorts. #Parkinsons #ParkinsonsDisease #ClinicalTrialsInProgress Prevail Therapeutics Eli Lilly and Company Read more: https://lnkd.in/ezYappQP